Progress of drugs in non-small cell lung cancer with brain metastasis
CAI Zhongfu
OUYANG Xuenong
YU Zongyang
Abstract：Non-small cell lung cancer( NSCLC) is one of the most common malignant tumor and a major cause of death from cancer. NSCLC patients often poorly responds to chemotherapy and has a relatively poor prognosis, especially in those patients with brain metastases. NSCLC patients with brain metastases have poor prognosis and worse quality of life;the natural median survival time is only 1-2 months. To some extent,whole brain radiation therapy improves quality of life and prolongs the survival time in NSCLC pa-tients with brain metastases;but the curative effects are still unsatisfactory.In recent years,some research around pemetrexed,temozolo-mide and epidermal growth factor receptor-tyrosine kinase inhibitors( EGFR-TKIs) are conducted and achieves certain results. In this paper,we review the progress of drugs in NSCLC with brain metastasis.
Keywords：Non-small cell lung cancer (NSCLC)Brain metastasisCytotoxic drugsEpidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 379-382 )